Now live: European new issue coverage and historical data, for free. → Explore All Content & Delivery Channels
Log In
No results found for "".

Commentary & Deal Flow

PX TALK: Biogroup E750m 7NC3 sr sec 3.25-3.50%; E250m 8NC3 sr unsec 5-5.25%

HYC European Market: Deal Flow - General

Biogroup EUR1bn 144A/Reg S 2-part. Via JPM (B&D)/BNP/Natixis joint glocos/Citi/CA/DB/GS/HSBC joint books. List Lux. NY law.

- CAB EUR750m sr sec notes due 2028 (7y). NC3 (50%,25%,par). Equity claw: 3y 40%. B2/B-/B+ (negative/stable/stable). Special call: 10% per year the 1st 3 years at 103. IPT mid to high 3s. Px talk: 3.25%-3.50%.

- Laboratoire Eimer EUR250m sr notes due 2029 (8y). NC3 (50%,25%,par). Equity claw: 3y 40%. Caa1/CCC/CCC+ (negative/stable/stable). IPT mid 5s. Px talk: 5.00%-5.25%.

Did investor call at 10am UKT 01/25. Virtual meetings available 01/25-27. Books close at 10am UKT tomorrow. Pricing tomorrow. UOP: along with a new EUR1.5bn term loan and EUR80m cash on hand, to repay its existing EUR2.015bn term loan, existing EUR305m 2nd lien debt and existing EUR219m PIK notes. Biz: Leading private medical laboratory testing business in France and Belgium.

We use functional cookies to make this site work properly and marketing cookies to personalize content. By continuing or clicking "Ok", you consent to our use of cookies. See our Cookie Policy for more information.
By continuing, you agree to FINSIGHT's Terms of Use and Privacy Policy.